N Engl J Med 391:299310 Ma J, Liu Y, Hu J, Liu X, Xia Y, Xia W, Shen Z, Kong X, Wu X, Mao L, Li Q (2025) Tirzepatide administration improves cognitive impairment in HFD mice by regulating the SIRT3-NLRP3 axis
GLP1 meals would be more 40/55/5, Protein/Fat/Carbs
There could be a way around this uptake problem though
Driven by a 10-year, 3-step plan created and publicized by Novo Nordisk to build the ob*sity care market from scratch to maximize their GLP-1 weight loss drug profits (which Louise Adams and I will discuss in-depth on our podcast), we have seen a combination of factors including (but certainly not limited to): Astroturf patient-advocacy groups working hard to influence not just patient and provider behavior, but also public health messaging, government and policy Extremely sketchy research creating misleading messages everything from body size itself, to the realities of the drugs, to how much weight is regained when people go off the drugs and much, much more Education created by the weight loss industry delivered directly to healthcare providers Its no wonder that there is so much confusion about informed consent for these drugs